- Home
- AIIO vs TPST Comparison
AIIO vs TPST Comparison
Compare AIIO & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIIO | TPST |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United Arab Emirates | United States |
| Employees | 68 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.5M | 30.9M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | AIIO | TPST |
|---|---|---|
| Price | $0.91 | $2.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 318.2K | 278.7K |
| Earning Date | 05-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.07 | $1.50 |
| 52 Week High | $2.82 | $12.22 |
Technical Indicators
Market Signals| Indicator | AIIO | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 71.47 | 52.45 |
| Support Level | $0.55 | $1.57 |
| Resistance Level | $1.18 | $2.48 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 46.05 | 67.59 |
Price Performance
Historical ComparisonAbout AIIO Robo.ai Inc. Class B Ordinary Shares
Robo.ai Inc is a pioneering smart electric vehicle company which aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology into a passenger-centric green premium mobility solution to the world. Geographically, the company operates in The United States, The United Arab Emirates, Mainland China.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.